Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 12, 2026
DataAggregated Company Financials
Companies5
  • 7D-6.5%
  • 3M-20.1%
  • 1Y-2.6%
  • YTD-17.3%

Over the last 7 days, the Biotech industry has dropped 6.5%, driven by pullbacks from every company within the industry. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are expected to grow by 2.2% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 13 Mar 2026DKK 141.7bDKK 40.2bDKK 15.0b5.8x9.4x3.5x
Sun, 08 Feb 2026DKK 164.8bDKK 40.4bDKK 18.9b6.1x8.7x4.1x
Tue, 06 Jan 2026DKK 171.0bDKK 40.6bDKK 19.0b6.2x9x4.2x
Thu, 04 Dec 2025DKK 174.8bDKK 40.7bDKK 19.0b6.1x9.2x4.3x
Sat, 01 Nov 2025DKK 168.5bDKK 39.2bDKK 16.9b12.7x10x4.3x
Mon, 29 Sep 2025DKK 162.7bDKK 38.9bDKK 16.8b12.5x9.7x4.2x
Wed, 27 Aug 2025DKK 145.7bDKK 39.0bDKK 16.8b11x8.7x3.7x
Fri, 25 Jul 2025DKK 138.7bDKK 26.8bDKK 7.3b13.3x19x5.2x
Sun, 22 Jun 2025DKK 125.7bDKK 27.2bDKK 7.4b10.9x16.9x4.6x
Tue, 20 May 2025DKK 125.1bDKK 28.0bDKK 7.9b10.2x15.8x4.5x
Thu, 17 Apr 2025DKK 124.4bDKK 27.3bDKK 7.7b11.2x16.2x4.6x
Sat, 15 Mar 2025DKK 144.9bDKK 27.3bDKK 7.7b12.3x18.9x5.3x
Mon, 10 Feb 2025DKK 153.8bDKK 26.0bDKK 4.7b15.5x32.8x5.9x
Wed, 08 Jan 2025DKK 168.0bDKK 26.0bDKK 4.7b17.8x35.8x6.5x
Fri, 06 Dec 2024DKK 167.9bDKK 26.0bDKK 4.7b17.2x35.8x6.5x
Sun, 03 Nov 2024DKK 175.7bDKK 25.5bDKK 5.5b20.9x32.1x6.9x
Tue, 01 Oct 2024DKK 179.6bDKK 25.5bDKK 5.5b22.1x32.8x7x
Thu, 29 Aug 2024DKK 201.2bDKK 25.5bDKK 5.5b25.3x36.8x7.9x
Sat, 27 Jul 2024DKK 201.2bDKK 24.8bDKK 5.6b18.4x35.7x8.1x
Mon, 24 Jun 2024DKK 176.3bDKK 24.8bDKK 5.6b16.7x31.3x7.1x
Wed, 22 May 2024DKK 182.2bDKK 24.8bDKK 5.6b18.7x32.4x7.3x
Fri, 19 Apr 2024DKK 178.8bDKK 23.9bDKK 5.0b18.8x35.5x7.5x
Sun, 17 Mar 2024DKK 190.0bDKK 23.9bDKK 5.0b19.6x37.8x7.9x
Tue, 13 Feb 2024DKK 168.2bDKK 23.3bDKK 4.2b23.2x40.4x7.2x
Thu, 11 Jan 2024DKK 182.4bDKK 23.3bDKK 4.2b26.1x43.8x7.8x
Sat, 09 Dec 2023DKK 182.3bDKK 23.3bDKK 4.2b26.3x43.8x7.8x
Mon, 06 Nov 2023DKK 161.8bDKK 22.0bDKK 4.7b19.2x34.1x7.3x
Wed, 04 Oct 2023DKK 190.2bDKK 22.0bDKK 4.7b22.2x40.2x8.6x
Fri, 01 Sep 2023DKK 199.9bDKK 22.0bDKK 4.7b23.7x42.3x9.1x
Sun, 30 Jul 2023DKK 201.6bDKK 19.5bDKK 4.4b35.3x45.8x10.3x
Tue, 27 Jun 2023DKK 201.2bDKK 19.5bDKK 4.4b41.8x45.7x10.3x
Thu, 25 May 2023DKK 216.5bDKK 19.5bDKK 4.4b43.2x49.1x11.1x
Sat, 22 Apr 2023DKK 210.8bDKK 17.9bDKK 3.5b32.9x59.6x11.8x
Mon, 20 Mar 2023DKK 190.4bDKK 17.9bDKK 3.5b29.7x53.7x10.6x
Price to Earnings Ratio

53.7x


Total Market Cap: DKK 190.4bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 30.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.4x which is lower than its 3-year average PE of 30.4x.
  • The 3-year average PS ratio of 6.9x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 62% per year over the last three years.
  • Revenues for these companies have grown 31% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-1.43%
Healthcare-0.12%
Biotech-6.51%
Biotech-6.51%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available

Latest News

ZEAL
DKK 262.80
Zealand Pharma
7D
-28.8%
1Y
-56.3%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
BAVA
DKK 177.65
Bavarian Nordic
7D
-5.3%
1Y
8.6%

BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside

Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.
GMAB
DKK 1,740.50
Genmab
7D
-1.9%
1Y
27.3%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
BIOPOR
DKK 0.93
BioPorto
7D
-1.5%
1Y
-35.4%
STRAP
DKK 556.00
Strategic Partners
7D
-4.1%
1Y
-21.8%